Cargando…

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy

AIM: To determine influence of neoadjuvant-chemotherapy (NAC) over tumor-infiltrating-lymphocytes (TIL) in triple-negative-breast-cancer (TNBC). METHODS: TILs were evaluated in 98 TNBC cases who came to Instituto Nacional de Enfermedades Neoplasicas from 2005 to 2010. Immunohistochemistry staining f...

Descripción completa

Detalles Bibliográficos
Autores principales: Castaneda, Carlos A, Mittendorf, Elizabeth, Casavilca, Sandro, Wu, Yun, Castillo, Miluska, Arboleda, Patricia, Nunez, Teresa, Guerra, Henry, Barrionuevo, Carlos, Dolores-Cerna, Ketty, Belmar-Lopez, Carolina, Abugattas, Julio, Calderon, Gabriela, De La Cruz, Miguel, Cotrina, Manuel, Dunstan, Jorge, Gomez, Henry L, Vidaurre, Tatiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056330/
https://www.ncbi.nlm.nih.gov/pubmed/27777881
http://dx.doi.org/10.5306/wjco.v7.i5.387
_version_ 1782458876135735296
author Castaneda, Carlos A
Mittendorf, Elizabeth
Casavilca, Sandro
Wu, Yun
Castillo, Miluska
Arboleda, Patricia
Nunez, Teresa
Guerra, Henry
Barrionuevo, Carlos
Dolores-Cerna, Ketty
Belmar-Lopez, Carolina
Abugattas, Julio
Calderon, Gabriela
De La Cruz, Miguel
Cotrina, Manuel
Dunstan, Jorge
Gomez, Henry L
Vidaurre, Tatiana
author_facet Castaneda, Carlos A
Mittendorf, Elizabeth
Casavilca, Sandro
Wu, Yun
Castillo, Miluska
Arboleda, Patricia
Nunez, Teresa
Guerra, Henry
Barrionuevo, Carlos
Dolores-Cerna, Ketty
Belmar-Lopez, Carolina
Abugattas, Julio
Calderon, Gabriela
De La Cruz, Miguel
Cotrina, Manuel
Dunstan, Jorge
Gomez, Henry L
Vidaurre, Tatiana
author_sort Castaneda, Carlos A
collection PubMed
description AIM: To determine influence of neoadjuvant-chemotherapy (NAC) over tumor-infiltrating-lymphocytes (TIL) in triple-negative-breast-cancer (TNBC). METHODS: TILs were evaluated in 98 TNBC cases who came to Instituto Nacional de Enfermedades Neoplasicas from 2005 to 2010. Immunohistochemistry staining for CD3, CD4, CD8 and FOXP3 was performed in tissue microarrays (TMA) sections. Evaluation of H/E in full-face and immunohistochemistry in TMA sections was performed in pre and post-NAC samples. STATA software was used and P value < 0.05 was considered statistically significant. RESULTS: Higher TIL evaluated in full-face sections from pre-NAC tumors was associated to pathologic-complete-response (pCR) (P = 0.0251) and outcome (P = 0.0334). TIL evaluated in TMA sections showed low level of agreement with full-face sections (ICC = 0.017-0.20) and was not associated to pCR or outcome. TIL in post-NAC samples were not associated to response or outcome. Post-NAC lesions with pCR had similar TIL levels than those without pCR (P = 0.6331). NAC produced a TIL decrease in full-face sections (P < 0.0001). Percentage of TIL subpopulations was correlated with their absolute counts. Higher counts of CD3, CD4, CD8 and FOXP3 in pre-NAC samples had longer disease-free-survival (DFS). Higher counts of CD3 in pre-NAC samples had longer overall-survival. Higher ratio of CD8/CD4 counts in pre-NAC was associated with pCR. Higher ratio of CD4/FOXP3 counts in pre-NAC was associated with longer DFS. Higher counts of CD4 in post-NAC samples were associated with pCR. CONCLUSION: TIL in pre-NAC full-face sections in TNBC are correlated to longer survival. TIL in full-face differ from TMA sections, absolute count and percentage analysis of TIL subpopulation closely related.
format Online
Article
Text
id pubmed-5056330
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-50563302016-10-24 Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy Castaneda, Carlos A Mittendorf, Elizabeth Casavilca, Sandro Wu, Yun Castillo, Miluska Arboleda, Patricia Nunez, Teresa Guerra, Henry Barrionuevo, Carlos Dolores-Cerna, Ketty Belmar-Lopez, Carolina Abugattas, Julio Calderon, Gabriela De La Cruz, Miguel Cotrina, Manuel Dunstan, Jorge Gomez, Henry L Vidaurre, Tatiana World J Clin Oncol Basic Study AIM: To determine influence of neoadjuvant-chemotherapy (NAC) over tumor-infiltrating-lymphocytes (TIL) in triple-negative-breast-cancer (TNBC). METHODS: TILs were evaluated in 98 TNBC cases who came to Instituto Nacional de Enfermedades Neoplasicas from 2005 to 2010. Immunohistochemistry staining for CD3, CD4, CD8 and FOXP3 was performed in tissue microarrays (TMA) sections. Evaluation of H/E in full-face and immunohistochemistry in TMA sections was performed in pre and post-NAC samples. STATA software was used and P value < 0.05 was considered statistically significant. RESULTS: Higher TIL evaluated in full-face sections from pre-NAC tumors was associated to pathologic-complete-response (pCR) (P = 0.0251) and outcome (P = 0.0334). TIL evaluated in TMA sections showed low level of agreement with full-face sections (ICC = 0.017-0.20) and was not associated to pCR or outcome. TIL in post-NAC samples were not associated to response or outcome. Post-NAC lesions with pCR had similar TIL levels than those without pCR (P = 0.6331). NAC produced a TIL decrease in full-face sections (P < 0.0001). Percentage of TIL subpopulations was correlated with their absolute counts. Higher counts of CD3, CD4, CD8 and FOXP3 in pre-NAC samples had longer disease-free-survival (DFS). Higher counts of CD3 in pre-NAC samples had longer overall-survival. Higher ratio of CD8/CD4 counts in pre-NAC was associated with pCR. Higher ratio of CD4/FOXP3 counts in pre-NAC was associated with longer DFS. Higher counts of CD4 in post-NAC samples were associated with pCR. CONCLUSION: TIL in pre-NAC full-face sections in TNBC are correlated to longer survival. TIL in full-face differ from TMA sections, absolute count and percentage analysis of TIL subpopulation closely related. Baishideng Publishing Group Inc 2016-10-10 2016-10-10 /pmc/articles/PMC5056330/ /pubmed/27777881 http://dx.doi.org/10.5306/wjco.v7.i5.387 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Basic Study
Castaneda, Carlos A
Mittendorf, Elizabeth
Casavilca, Sandro
Wu, Yun
Castillo, Miluska
Arboleda, Patricia
Nunez, Teresa
Guerra, Henry
Barrionuevo, Carlos
Dolores-Cerna, Ketty
Belmar-Lopez, Carolina
Abugattas, Julio
Calderon, Gabriela
De La Cruz, Miguel
Cotrina, Manuel
Dunstan, Jorge
Gomez, Henry L
Vidaurre, Tatiana
Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
title Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
title_full Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
title_fullStr Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
title_full_unstemmed Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
title_short Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
title_sort tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
topic Basic Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056330/
https://www.ncbi.nlm.nih.gov/pubmed/27777881
http://dx.doi.org/10.5306/wjco.v7.i5.387
work_keys_str_mv AT castanedacarlosa tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT mittendorfelizabeth tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT casavilcasandro tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT wuyun tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT castillomiluska tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT arboledapatricia tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT nunezteresa tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT guerrahenry tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT barrionuevocarlos tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT dolorescernaketty tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT belmarlopezcarolina tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT abugattasjulio tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT calderongabriela tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT delacruzmiguel tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT cotrinamanuel tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT dunstanjorge tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT gomezhenryl tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy
AT vidaurretatiana tumorinfiltratinglymphocytesintriplenegativebreastcancerreceivingneoadjuvantchemotherapy